aluates Reports

$ 0.0

Automative

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research Report 2024

Published Date: May 2024

Report Code: QYRE-Auto-22E17153

BUY CHAPTERS

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research Report 2024

Code: QYRE-Auto-22E17153

Report

May 2024

Pages:84

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Teva Pharmaceutical Industries

GlaxoSmithKline PLC

GlaxoSmithKline

Pfizer Inc

Vendors

Astrazeneca plc

Merck

Myriad Genetics

Johnson & Johnson

AbbVie

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market

The global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors include Pfizer, AstraZeneca, Merck & Co, Myriad Genetics, GlaxoSmithKline, Johnson & Johnson, AbbVie, Teva Pharmaceutical Industries, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poly (ADP-Ribose) Polymerase (PARP) Inhibitors.

The Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report

Report Metric	Details
Report Name	Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market
Segment by Type	Talazoparib Veliparib Olaparib Other
Segment by Application	Ovarian Cancer Breast Cancer Fallopian Tube Cancer Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, AstraZeneca, Merck & Co, Myriad Genetics, GlaxoSmithKline, Johnson & Johnson, AbbVie, Teva Pharmaceutical Industries
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market report?

Ans: The main players in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market are Pfizer, AstraZeneca, Merck & Co, Myriad Genetics, GlaxoSmithKline, Johnson & Johnson, AbbVie, Teva Pharmaceutical Industries

What are the Application segmentation covered in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market report?

Ans: The Applications covered in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market report are Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Other

What are the Type segmentation covered in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market report?

Ans: The Types covered in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market report are Talazoparib, Veliparib, Olaparib, Other

1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview

1.1 Product Definition

1.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type

1.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value Comparison by Type (2024-2030)

1.2.2 Talazoparib

1.2.3 Veliparib

1.2.4 Olaparib

1.2.5 Other

1.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application

1.3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application (2024-2030)

1.3.2 Ovarian Cancer

1.3.3 Breast Cancer

1.3.4 Fallopian Tube Cancer

1.3.5 Other

1.4 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue 2019-2030

1.4.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales 2019-2030

1.4.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competition by Manufacturers

2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Manufacturers (2019-2024)

2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Date of Enter into This Industry

2.8 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Situation and Trends

2.8.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Players Market Share by Revenue

2.8.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Scenario by Region

3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2019-2030

3.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2019-2024

3.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region: 2025-2030

3.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2019-2030

3.3.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2019-2024

3.3.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2025-2030

3.4 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country

3.4.1 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2030)

3.4.3 North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country

3.5.1 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2030)

3.5.3 Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2019-2030)

3.6.3 Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2030)

3.7.3 Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2030)

3.8.3 Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2019-2030)

4.1.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2019-2024)

4.1.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Type (2025-2030)

4.1.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2019-2030)

4.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2019-2030)

4.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2019-2024)

4.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Type (2025-2030)

4.2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2019-2030)

4.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price by Type (2019-2030)

5 Segment by Application

5.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2019-2030)

5.1.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2019-2024)

5.1.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Application (2025-2030)

5.1.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2019-2030)

5.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2019-2030)

5.2.1 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2019-2024)

5.2.2 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Application (2025-2030)

5.2.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2019-2030)

5.3 Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Merck & Co

6.3.1 Merck & Co Company Information

6.3.2 Merck & Co Description and Business Overview

6.3.3 Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.3.5 Merck & Co Recent Developments/Updates

6.4 Myriad Genetics

6.4.1 Myriad Genetics Company Information

6.4.2 Myriad Genetics Description and Business Overview

6.4.3 Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.4.5 Myriad Genetics Recent Developments/Updates

6.5 GlaxoSmithKline

6.5.1 GlaxoSmithKline Company Information

6.5.2 GlaxoSmithKline Description and Business Overview

6.5.3 GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.5.4 GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.5.5 GlaxoSmithKline Recent Developments/Updates

6.6 Johnson & Johnson

6.6.1 Johnson & Johnson Company Information

6.6.2 Johnson & Johnson Description and Business Overview

6.6.3 Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.6.5 Johnson & Johnson Recent Developments/Updates

6.7 AbbVie

6.7.1 AbbVie Company Information

6.7.2 AbbVie Description and Business Overview

6.7.3 AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.7.4 AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.7.5 AbbVie Recent Developments/Updates

6.8 Teva Pharmaceutical Industries

6.8.1 Teva Pharmaceutical Industries Company Information

6.8.2 Teva Pharmaceutical Industries Description and Business Overview

6.8.3 Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Portfolio

6.8.5 Teva Pharmaceutical Industries Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry Chain Analysis

7.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Production Mode & Process

7.4 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales and Marketing

7.4.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Channels

7.4.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Distributors

7.5 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Customers

8 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Dynamics

8.1 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry Trends

8.2 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Drivers

8.3 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Challenges

8.4 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Teva Pharmaceutical Industries

GlaxoSmithKline PLC

GlaxoSmithKline

Pfizer Inc

Vendors

Astrazeneca plc

Merck

Myriad Genetics

Johnson & Johnson

AbbVie

List of Tables

Table 1. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Situation by Manufacturers in 2023

Table 4. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Poly (ADP-Ribose) Polymerase (PARP) Inhibitors as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2019-2024) & (K Units)

Table 18. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2019-2024)

Table 19. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2025-2030) & (K Units)

Table 20. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2025-2030)

Table 21. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2019-2024)

Table 23. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2025-2030)

Table 25. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2024) & (K Units)

Table 27. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2025-2030) & (K Units)

Table 28. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2024) & (K Units)

Table 32. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2025-2030) & (K Units)

Table 33. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Type (2019-2024)

Table 51. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Type (2025-2030)

Table 52. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2019-2024)

Table 53. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Type (2025-2030)

Table 54. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2019-2024)

Table 57. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Type (2025-2030)

Table 58. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2019-2024)

Table 59. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2025-2030)

Table 60. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Application (2019-2024)

Table 61. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units) by Application (2025-2030)

Table 62. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2019-2024)

Table 63. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Application (2025-2030)

Table 64. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2019-2024)

Table 67. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Application (2025-2030)

Table 68. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2019-2024)

Table 69. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2025-2030)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Pfizer Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 74. Pfizer Recent Developments/Updates

Table 75. AstraZeneca Company Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. AstraZeneca Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Merck & Co Company Information

Table 81. Merck & Co Description and Business Overview

Table 82. Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Merck & Co Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 84. Merck & Co Recent Developments/Updates

Table 85. Myriad Genetics Company Information

Table 86. Myriad Genetics Description and Business Overview

Table 87. Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Myriad Genetics Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 89. Myriad Genetics Recent Developments/Updates

Table 90. GlaxoSmithKline Company Information

Table 91. GlaxoSmithKline Description and Business Overview

Table 92. GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. GlaxoSmithKline Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 94. GlaxoSmithKline Recent Developments/Updates

Table 95. Johnson & Johnson Company Information

Table 96. Johnson & Johnson Description and Business Overview

Table 97. Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Johnson & Johnson Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 99. Johnson & Johnson Recent Developments/Updates

Table 100. AbbVie Company Information

Table 101. AbbVie Description and Business Overview

Table 102. AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. AbbVie Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 104. AbbVie Recent Developments/Updates

Table 105. Teva Pharmaceutical Industries Company Information

Table 106. Teva Pharmaceutical Industries Description and Business Overview

Table 107. Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Teva Pharmaceutical Industries Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product

Table 109. Teva Pharmaceutical Industries Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Distributors List

Table 113. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Customers List

Table 114. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends

Table 115. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Drivers

Table 116. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Challenges

Table 117. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

Figure 2. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Type: 2023 & 2030

Figure 4. Talazoparib Product Picture

Figure 5. Veliparib Product Picture

Figure 6. Olaparib Product Picture

Figure 7. Other Product Picture

Figure 8. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Figure 9. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Application: 2023 & 2030

Figure 10. Ovarian Cancer

Figure 11. Breast Cancer

Figure 12. Fallopian Tube Cancer

Figure 13. Other

Figure 14. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size (2019-2030) & (US$ Million)

Figure 16. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales (2019-2030) & (K Units)

Figure 17. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Average Price (US$/Unit) & (2019-2030)

Figure 18. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Report Years Considered

Figure 19. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Share by Manufacturers in 2023

Figure 20. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Share by Manufacturers in 2023

Figure 21. Global 5 and 10 Largest Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Players: Market Share by Revenue in Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in 2023

Figure 22. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 23. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 24. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2019-2030)

Figure 25. North America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2019-2030)

Figure 26. United States Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Canada Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2019-2030)

Figure 29. Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2019-2030)

Figure 30. Germany Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. France Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. U.K. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Italy Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Russia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Region (2019-2030)

Figure 36. Asia Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Region (2019-2030)

Figure 37. China Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Japan Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. South Korea Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. India Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Australia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. China Taiwan Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2019-2030)

Figure 45. Mexico Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Brazil Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Argentina Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Colombia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Sales Market Share by Country (2019-2030)

Figure 50. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Market Share by Country (2019-2030)

Figure 51. Turkey Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Saudi Arabia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. UAE Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Global Sales Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type (2019-2030)

Figure 55. Global Revenue Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Type (2019-2030)

Figure 56. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Type (2019-2030)

Figure 57. Global Sales Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application (2019-2030)

Figure 58. Global Revenue Market Share of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Application (2019-2030)

Figure 59. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Price (US$/Unit) by Application (2019-2030)

Figure 60. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Value Chain

Figure 61. Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Production Process

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global PARP Poly ADP ribose Polymerase Inhibitors Market Insights Forecast to 2030

DNA Repair PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Enzyme Poly ADP Ribose Polymerase PARP Inhibitor Market Insights Forecast to 2030

Global PARP Inhibitor Biomarkers Service Market Research Report 2024

Prostate Cancer PARP Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market Insights Forecast to 2030

Global PARP Inhibitor Biomarkers Testing Product Market Research Report 2024

PARP Inhibitors for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global PARP1 Antibody Market Research Report 2024

Global PARP Poly ADP Ribose Polymerase Inhibitor Market Research Report 2025

Global PORCN Inhibitor Market Research Report 2024

Cancer Drug based on PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Poly A Polymerase Market Research Report 2024

Global RNase Inhibitor Market Research Report 2025

Global Tankyrase Inhibitors Market Research Report 2025

Global Polymer Oxidation Inhibitors Market Research Report 2025

Global FAP Inhibitor Market Research Report 2024

Global Mitogen Activated Protein Kinase MAPK Inhibitors Therapeutics Market Research Report 2024

Global Oxidation Inhibitors Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions